Optogenetic Cardiac Modulation for Arrhythmia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for arrhythmias associated with abnormalities in cardiac action-potential morphology, such as long or short QT syndromes, are inadequate as they lack spatial or temporal resolution, leading to significant side effects and irreversible damage, and existing implantable devices cannot address the underlying cause of arrhythmias.
Innovation Solution
The use of optogenetic tools to modulate action potential properties in cardiac tissue cells by expressing light-sensitive channels like ChR2 or ACR2, allowing for precise control of action potential duration and repolarization heterogeneities through light-induced stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are used to treat arrhythmias, then arrhythmia treatment is achieved, but spatial and temporal resolution is lacking leading to significant side effects
Solution Approach 1:
The patent applies optogenetic tools to selectively modulate action potential properties in specific regions of cardiac tissue affected by arrhythmias, rather than applying global drug treatment. This localized approach allows precise correction of repolarization abnormalities in affected areas while preserving normal function in healthy tissue, thereby reducing side effects while maintaining treatment effectiveness.
Solution Approach 2:
The patent replaces conventional pharmacological mechanisms with optogenetic mechanisms. Instead of using drugs that non-specifically bind to ion channels and affect global cardiac electrophysiology, the invention uses light-sensitive opsins that can be selectively activated by light to precisely control ion channel activity in specific tissue regions, achieving targeted arrhythmia treatment with fewer side effects.
2Reliability
If catheter ablation and surgery are used, then arrhythmia treatment is achieved, but irreversible damage occurs and is limited to minority of patients
Solution Approach 1:
The patent employs dynamic optogenetic modulation that can be activated and deactivated on demand through light stimulation. This reversible approach allows real-time control of action potential properties to terminate or prevent arrhythmias without causing permanent tissue damage, unlike catheter ablation which creates irreversible lesions. The treatment can be dynamically adjusted based on patient needs and arrhythmia occurrence.
Solution Approach 2:
The patent introduces light-sensitive opsin proteins as intermediary molecules that mediate between light signals and ion channel activity. These opsins act as reversible switches that can be activated by light to modulate electrical properties of cardiac cells, providing a non-invasive and reversible mechanism to treat arrhythmias without the irreversible damage associated with surgical ablation.
3Reliability
If implantable cardiac defibrillator is used, then life-saving protection is achieved, but underlying problem is not solved and treatment is painful
Solution Approach 1:
The patent implements a feedback mechanism where optogenetic tools can be activated in response to detected arrhythmias to restore normal action potential properties. This closed-loop approach addresses the underlying electrophysiological abnormalities causing arrhythmias rather than merely suppressing their expression, providing life-saving protection while potentially eliminating the need for painful defibrillation shocks by treating the root cause.
4Ease of operation
If electrical stimulation is used in implantable devices, then pacing and defibrillation are achieved, but action potential morphology is not altered and underlying cause cannot be treated
Solution Approach 1:
The patent changes the fundamental parameter of intervention from electrical stimulation to optical stimulation. By expressing light-sensitive opsins in cardiac tissue, the invention enables modulation of action potential morphology through light-induced changes in ion channel activity. This allows direct alteration of the electrophysiological parameters (action potential duration, repolarization characteristics) that underlie arrhythmias, rather than merely pacing or shock therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively normalizes pathological action potential properties, suppresses arrhythmogenicity, and prevents or terminates arrhythmias by bidirectionally modulating action potential duration, thereby offering a more targeted and reversible treatment for arrhythmias.
Implementation Method 1
illuminating the cardiac tissue cells during the action potential
Data Source
AI summary
The present invention relates to products and methods for modulating cardiac function.